Aceragen Inc IDRA

Primary Symbol: ACGN

Healthcare Biotechnology

Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.

NDAQ:ACGN - Post by User

Aceragen Inc

Bullboard Posts

Post by DartStockon Nov 02, 2010 9:28am

404 Views

Post# 17644098

Going to jump aboard?

If you like to buy low and sell high this, company engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, could be your ticket to higher elevations.

.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide